Haarberg 3D Center
The Haarberg 3D Center is a center for excellence in drug development. The primary objective of the -funded Haarberg 3D Center is to develop an integrated drug, disease and delivery (3D) framework for drug development and build university, industry and clinical partnerships to accelerate the translation of new treatments for cancer and other diseases.
The Haarberg 3D Center's work is possible through grant funding and because of Kevin and Lorie Haarberg. The Haarberg 3D Center was established in 2021 through a five-year, $3.9 million award from the South Dakota Research and Commercialization Council and a $1.1 million gift from the Haarbergs. Additional grant funding also facilitates center work. In fiscal year 2023, $2.75 million in external grant funding was brought in for Haarberg 3D Center projects. Kevin and Lorie Haarberg have been key partners of SDSU’s Department of Pharmaceutical Sciences since 2010 and have a planned gift of an additional $10 million for the center, ensuring continued success of Haarberg 3D Center work.
Drug repurposing is a key focus of Haarberg 3D Center research. Development and distribution of new drugs can consume extensive time and resources. Drug repurposing involves research into the modification of existing drugs for new purposes, evaluation of existing drugs for additional or alternative applications or resynthesis of existing drugs. It can significantly reduce the time and resources needed to bring a new drug to the market. The Haarberg 3D Center has set a goal to repurpose, reapply or resynthesize a drug by 2030.
Our Mission and Vision
The vision of the Haarberg 3D Center is to become a nationally recognized and locally relevant center of excellence for drug development. The center’s mission is to build the infrastructure, partnerships and network for the translation and commercialization of new treatments for cancer and other diseases, vis-à-vis train the biomedical workforce and create jobs to promote economic development in the state. The center will integrate the existing multidisciplinary strengths in drug, disease and delivery research at South Dakota State University, and other universities, clinical and industry partners to develop and commercialize technologies for human and animal diseases.
Goal 1: Development and translation of new treatments for cancer and other diseases. The Haarberg 3D Center will leverage the current intellectual property portfolio to match industry needs to expedite the preclinical and clinical development of new treatments for cancer and other diseases.
Goal 2: Development of new intellectual property or technologies for animal and human health. The Haarberg 3D Center will issue requests for proposals to support pipeline projects and new projects in animal and human health. The seed grant program will be used to generate preliminary data for external funding, develop partnerships and advance research commercialization.
Goal 3: Foster entrepreneurship and strengthen the biomedical and pharmaceutical workforce in the state. The Haarberg 3D Center will conduct training workshops for faculty, postdoctoral students and graduate students in the areas of drug development, regulatory approval, intellectual property and entrepreneurship.
History
Kevin and Lorie Haarberg’s transformational gift represented a commitment of $1.1 million in seed-funding for the Haarberg 3D Center.
The center has two main projects and a series of pilot projects.
Wenfeng An
Wenfeng An is a professor in SDSU's Department of Pharmaceutical Sciences. An's pilot grant research focuses on the development of a cancer vaccine based in his LINE-1 research.
Saikat Basu
Saikat Basu is an assistant professor in SDSU’s Department of Mechanical Engineering. Basu’s work will seek to develop and design a digital platform that will assess the targeted delivery of a wide range of nasal spray and oral inhaler products.
Laura Brunmaier
Laura Brunmaier is an assistant research professor at South Dakota School of Mines and Technology. Her project is "Advancing translational cell culture: Optimization and distribution of a chemically-defined platform for endothelial cell research."
Kristi Egland
Kristi Egland, associate professor at the Sanford School of Medicine of the University of South Dakota and chief science officer and co-founder of Poly Solutions, LLC, discovered research as a career path her first year in college.
“I worked as an undergrad in a lab making solutions, using the autoclave and stocking the tissue culture room. During my junior year, I started performing my own experiments,” she said. “And I remember thinking, 'Wow, you can get paid to do this as a career!'”
That excitement for lab work helped her earn a bachelor’s degree in biology from Washington University and a Ph.D. in molecular biology at the University of Iowa. She became a postdoctoral fellow at the National Institutes of Health.
But it was a much more personal experience that would ultimately reshape her career and lead her down the path to the work that recently earned her a grant from the Haarberg 3D (Drug, Disease and Delivery) Research Center.
Life happens
Egland had already built a career studying cancer when cancer found her.
“I noticed that there was a lump in my breast,” she said. “It turned out to be a 4 centimeter tumor.”
At just 37, with two young children, she was diagnosed with triple negative breast cancer, an aggressive form of the disease. Unlike other types of breast cancer, it lacks the three most common targets for drug therapies, limiting treatment options.
“So, I had a cancer that just rapidly grows,” she explained.
Her treatment was equally aggressive: a bilateral mastectomy, eight rounds of chemotherapy and six weeks of radiation.
“It was… it was awful,” she said.
The experience reinforced something she already knew from her research but now understood on a deeply personal level. While treatment is possible if the cancer is caught early, what needs to be done to increase chances of a cure or survival can be devastating.
Rather than stepping away from science after her diagnosis, Egland leaned in, reshaping her work to focus more directly on research that would improve the lives of patients.
“I decided that I was done doing basic research, just figuring out the function of a single protein,” she said. “I wanted to do translational research and have a more direct impact on patient care, prognosis and quality of life.”
After recovery, Egland began a long career at Sanford Research in Sioux Falls, where she focused on molecular pathology and cancer biology and immunotherapy. She then took a turn at SAB BIO, a biotech company in Sioux Falls, where she coordinated drug discovery and genetic innovation.
Making new plans
Egland and her collaborator, Thomas Luke, decided to sharpen their own focus and launch their own company, Poly Solutions, to develop therapeutics for cancer and infectious diseases.
Their goal is to develop new kinds of cancer therapies that are more adaptable and potentially more effective than current treatments.
According to Egland, most current antibody therapies rely on monoclonal antibodies, which target a single marker on a cancer cell. But tumors evolve, and single-target treatments can stop working. The work of Poly Solutions is to change treatment by developing an approach inspired by how the human immune system naturally works.
Egland offers a simple analogy.
“Let’s say that the monoclonal antibody target is the star on top of a Christmas tree,” she said. “The polyclonal antibodies target the lights. They’re all around the tree.”
If the light on top of the tree burns out, the antibody can no longer recognize the target. But the lights, spread across the branches, still shine.
“Once the target gets mutated, monoclonal antibodies no longer work,” she said of single-target therapies. “But with the polyclonal therapies, there’s still plenty of shinning lights that can be bound.”
Egland’s current research focuses on developing polyclonal antibodies to fight multiple myeloma, a blood cancer that presents clearer entry points for immune-based treatments.
For Egland, effectiveness isn’t the only goal, however. Alleviating the harsh side effects of cancer treatment is also important.
“Antibodies, in general, have much lower side effects than chemotherapy,” she said.
Next steps
Today, Egland and her team are working to move their discoveries toward clinical trials, supported by early-stage grant funding and growing infrastructure. While she is careful not to promise too much, her optimism is clear.
“I really think polyclonal antibodies are the key to make a difference in the lives of cancer patients,” she said. “I’m so ready to make this therapy available as an option for treatment.”
Susan Immanuel
When Susan Immanuel talks about her research, one theme is clear. “I like solving puzzles,” she said.
At South Dakota State University’s College of Pharmacy and Allied Health Professions, Immanuel is applying that mindset to pancreatic cancer, exploring new ways to deliver effective cancer drugs more precisely and effectively to tumors.
Immanuel, a postdoctoral research associate in SDSU's pharmaceutical sciences department who recently earned a grant from the Haarberg Drug, Disease and Delivery (3D) Research Center, is focused on drug repurposing and advanced delivery systems. Her work centers on combining an existing FDA-approved drug with a standard pancreatic cancer treatment in a way that could significantly improve patient outcomes.
“When you give these two drugs together, you theoretically should see an exponential effect on shrinking the tumor,” Immanuel explained.
This approach also has practical advantages. Because the repurposed drug is already approved, it may reach the market and patients more quickly than a completely new therapy.
“Since it’s a repurposed drug, bringing it to market is easier and faster than developing and testing an entirely new drug,” she said.
For Immanuel, her Haarberg 3D Center project builds on years of research into drug delivery systems, an area she says is just as, if not more, important than the drug itself.
Better drug delivery systems ensure that medications actually reach the places in the body where they can make a difference. Many treatments lose their effectiveness before they ever reach their target. For example, most of an eye drop, including the drug in that drop, is simply washed away by tears, leaving only a small fraction of medication to penetrate the tissue. Even when drugs are delivered directly into the bloodstream, they circulate throughout the entire body, affecting both healthy and diseased cells, potentially forcing physicians to use higher, more toxic doses to achieve the desired effect.
That’s why many cancer therapies come with significant side effects.
“The drug affects everything,” she said. “That’s why when you give cancer drugs, people start losing their hair, as an example.”
Immanuel wants to change that.
“I want to develop a platform that can deliver the drug only to the specific tumor site rather than the whole body,” Immanuel said.
According to Immanuel, by designing drug delivery systems to precisely target specific tissues, these systems can guide therapies exactly where they are needed, concentrating their impact on a tumor, for instance, while sparing the rest of the body. As a result, treatments are not only more effective but also safer and better tolerated.
Fighting a 'Silent' Cancer
According to the American Cancer Society, although pancreatic cancer accounts for just 3% of all cancers in the United States, it is the third leading cause of cancer deaths. The uniquely complex challenges associated with pancreatic cancer contribute to its persistently low survival rates, underscoring the critical need for innovative approaches like those Immanuel is pursuing.
According to Immanuel, one major challenge in treating pancreatic cancer effectively is the lack of time that physicians have to treat pancreatic cancer. Symptoms are not obvious in this type of cancer, often called a “silent” killer.
“Most of the time, patients get diagnosed only in the later stages of the disease,” Immanuel said.
Symptoms of early-stage pancreatic cancer are easy to miss as they tend to mimic other health concerns such as indigestion or generalized stomach pain. In addition, the pancreas is located deep within the body, and tumors are difficult to feel during a physical exam.
The disease is difficult to treat effectively, as well. Even when therapies are available, tumors can quickly adapt.
“The cells develop resistance,” Immanuel said. “No matter what drug you give, the cells are going to change and grow.”
Another hurdle lies within the tumor itself. Pancreatic tumors include not only cancer cells but also surrounding tissue that can limit how drugs penetrate and work. To effectively treat the pancreatic cancer, the drug delivery system needs to navigate noncancer cells that actually make up the bulk of the tumor.
To better understand how treatments will perform, Immanuel and her mentors are using advanced 3D tumor models that more closely mimic real conditions in the body.
So far, the results are promising.
“The drug we selected and the delivery system we have designed are showing a really good effect on the 3D models too,” she said. “We’ve been having really good progress with this project.”
Immanuel's Journey to Cancer Fighter
Immanuel’s path to SDSU began in India, where she initially considered becoming a physician before choosing a scientific route. She completed her Ph.D. in nanotechnology at the PSG Institute of Advanced Studies before launching a research career, including work at the Aravind Medical Research Foundation and a postdoctoral appointment at the Texas A&M Health Science Center.
Her early work focused on the development of nanomaterials for biosensors that help in the diagnosis of eye diseases and neurological disorders. Over time, her focus shifted toward pharmaceutical sciences and combining repurposed drugs and better delivery systems. That transition eventually led her to SDSU, where she works closely with Sanku Mallik, SDSU associate dean of research and professor of pharmaceutical sciences, and Joshua Reineke, co-director of the Haarberg 3D Center and associate professor of pharmaceutical sciences.
She also collaborates with Sharon Prince, an internationally accomplished cancer scientist, at the University of Cape Town. According to Immanuel, Prince’s research team used artificial intelligence-driven database searches to identify a drug that showed particularly strong potential to fight cancers including skin, breast and pancreatic cancer. Immanuel’s role in the collaboration is to take that discovery to the next level by developing the right drug delivery system.
While the science of developing that system is complex, Immanuel’s motivation is simple: contribute to solving a problem that affects so many lives. Even small advances, she believes, are meaningful.
“The ultimate solution to this puzzle might take my entire career,” she said. “But I would like to make my contribution toward it.”
One carefully targeted solution at a time.
Tanvir Khaliq
Tanvir Khaliq is an assistant professor of pharmaceutical sciences at South Dakota State University. His project is "Rational development of novel analogs of the orally active antileishmanial lead natural product peganine."
Sunil Mor
Sunil Mor is an assistant professor in SDSU’s Department of Veterinary and Biomedical Sciences. Mor’s work will seek to develop and test a novel viral vectored vaccine to protect pigs against porcine reproductive and respiratory syndrome.
Tuğba Özdemir
Tuğba Özdemir is an assistant professor in the Department of Nanoscience and Biomedical Engineering at South Dakota School of Mines and Technology. Her project is "An HA filter capture device for the detection of cancer from plasma samples."
Joshua Reineke
Joshua Reineke is an associate professor and the director of the Haarberg 3D Center. His project is "Cost-effective combinatorial antibiotic pulmonary formulation to eradicate M. Abscesses infection."
Khosrow Rezvani
Khosrow Rezvani is an associate professor of cancer biology at the University of South Dakota Sanford School of Medicine. His project seeks to advance a treatment for colon cancer and prepare for pre-Investigational New Drug.
Rajesh Sani
Rajesh Sani is a professor of chemical and biological engineering at South Dakota School of Mines and Technology. His project is "ThermoEPS-conjugated nanogels for precisions drug delivery in solid tumors."
Jill Weimer
Jill Weimer is an associate professor at the Sanford School of Medicine of the University of South Dakota. Her project is "Modulating SORT1 pathways to correct lysosomal dysfunction in neuronal carotid lipofuscinoses."
Rachel Willand-Charnley
Rachel Willand-Charnley is an assistant professor in SDSU’s Department of Chemistry and Biochemistry. Willand-Charnley’s work will explore the use of antibody-enzyme conjugate to sensitize colon cancer cells to the immune system. The outcomes from this work will help in developing new therapeutic approaches for colon cancer.